The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

SIMPLE SUMMARY: Urothelial carcinoma is an aggressive cancer with a high risk of metastatic progression. Chemotherapy plays a key role in the management of metastatic urothelial carcinoma, with, however, no possibility of cure. Immune checkpoint inhibitors have significantly improved the outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Houssiau, Hélène, Seront, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997155/
https://www.ncbi.nlm.nih.gov/pubmed/35406412
http://dx.doi.org/10.3390/cancers14071640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997155/
https://www.ncbi.nlm.nih.gov/pubmed/35406412
http://dx.doi.org/10.3390/cancers14071640

Ejemplares similares